CSIMarket


Lumos Pharma Inc   (LUMO)
Other Ticker:  
 


 

Lumos Pharma Inc

LUMO's Financial Statements and Analysis



Lumos Pharma Inc increased forth quarter of 2023 net loss per share of $-1.15 compare to net loss per share of $-0.98 recorded in the same quarter a year ago a decrease compare to $-1.04 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -1.15 $  1 Mill
$-0.17     Unch.     +61.33 %



Lumos Pharma Inc 's Revenue rose by 61.33 % in forth quarter of 2023 (Dec 31 2023) year on year, to $1 million and advanced by 11700 % sequentially.


Lumos Pharma Inc is

More on LUMO's Income Statement



Lumos Pharma Inc 's in theforth quarter of 2023 recorded net loss of $-9.457 million, an increase from net loss of $-8.247 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on LUMO's Growth

Lumos Pharma Inc Inventories
In Dec 31 2023 company's net cash and cash equivalents decreased by $0 million


Lumos Pharma Inc does not pay out common stock dividend.

In trailing twelve-month period Lumos Pharma Inc payed $ -3.82 cash per share, on a free-cash flow basis .

Book value fell by -24.61 % sequentially to $3.35 per share, -26.23% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 3.35 per share from $ 4.45.

Company issued 0.16 million shares or 2.05 % in Dec 31 2023.


More on LUMO's Dividends

 Market Capitalization (Millions) 23
 Shares Outstanding (Millions) 8
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -34
 Cash Flow (TTM) (Millions $) -21
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Lumos Pharma Inc does not pay out common stock dividend.

In trailing twelve-month period Lumos Pharma Inc had negative $ -3.82 cash flow per share, on a free-cash flow basis .

Book value fell by -24.61 % sequentially to $3.35 per share, -26.23% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 3.35 per share from $ 4.45.

Company issued 0.16 million shares or 2.05 % in Dec 31 2023.


More on LUMO's Balance Sheets

 Market Capitalization (Millions) 23
 Shares Outstanding (Millions) 8
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -34
 Cash Flow (TTM) (Millions $) -21
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Lumos Pharma Inc Earnings

Lumos Pharma Inc Sees Remarkable 61.328% Jump in Revenue During Fourth Quarter of 2023

Lumos Pharma Inc, a pharmaceutical company, recently rel...

Lumos Pharma Inc. Reports Alarming Deficit Surge in Fiscal Year 2023

e: October 10, 2023
Lumos Pharma Inc., one of the major players in the pharmaceutical preparations industry, announced its third-quarter financial results for 2023, revealing a deteriorating performance compared to the same period last year. The company recorded a remarkable decline in revenue, plummeting by -98.592% to a meager $0.01 million. The shortfall per share also worsened, expanding to $-1.04 from the prior year's figure.
Contrary to Lumos Pharma's disappointing performance, the Major Pharmaceutical Preparations industry as a whole posted an increase in top-line growth during the third quarter of 2023. However, Lumos Pharma Inc. significantly underperformed its peers, experiencing a sharp de...

An Unusual Execution by Lumos Pharma Inc Shakes Up Q2 2023, Amidst Volatile Stock Performance



Lumos Pharma Inc, a major pharmaceutical preparations company, has recently released its financial results for the second quarter of 2023. While the company experienced a decline in its stock value over the past month, it saw a positive trend over the past five trading days. Furthermore, Lumos Pharma Inc's revenue surged in the second quarter of 2023 compared to the same period the previous year, yet the company reported an increased loss per share. This article aims to interpret these results and discuss their potential implications for Lumos Pharma Inc going forward.
1. Stock Performance:
Lumos Pharma Inc's stock declined by -13.8% during the preceding month. This decline may raise concer...

LUMO Shines Bright with Impressive Q1 Financial Performance

Lumos ...


Date modified: 2024-03-08T14:03:20+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com